ClinicalTrials.gg
RecruitingNCT07186634PROMPTUpdated Apr 17, 2026

PeRiOperative Medicine Platform Trial

A Phase 4 interventional study of Liberal inspired oxygen and Conservative inspired oxygen in Surgical Site Infection After Major Surgery, Anaesthesia and Major Complications, sponsored by Monash University. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Monash University · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Phase
Phase 4
Study type
Interventional
Enrollment
7,800
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Our specific aims are to investigate whether conservative (≤30%), intermediate (50%), or liberal (80%) inspired oxygen during and immediately after surgery: Aim 1: Reduces surgical site infections (SSIs or "wound infections") and other healthcare-associated infections (pneumonia and sepsis). Aim 2: Reduces a pooled composite of serious postoperative complications, leading to a faster and more complete recovery after surgery, and thus increases "days alive and at home up to 30 days after surgery" (DAH30). Primary hypothesis: Liberal (80%) oxygen concentration delivered with anesthesia in patients undergoing major surgery reduces the incidence of SSIs after surgery compared to conservative (≤30%) or intermediate (50%) oxygen concentration. Secondary hypothesis: Hyperoxia (50-80%) delivered with anesthesia in patients undergoing major surgery increases the incidence of pulmonary and other complications after surgery compared to conservative (≤30%) oxygen concentration, resulting in fewer Days At Home (DAH). PROMPT enrolls patients undergoing elective or semi-elective surgery.

Read the detailed description

www.promptssi.org.au

02

Conditions studied

  • Surgical Site Infection After Major Surgery
  • Anaesthesia
  • Major Complications
  • Quality of Recovery (QoR-15)
  • Quality of Life

Keywords

  • Anaesthesiology, complications, oxygen, surgery
  • platform trial
03

In context

Surgical Wound Infection

745 studies on the registry are indexed under Surgical Wound Infection; 151 are open to participants now.

This study's planned enrollment of 7,800 is above the median of 200 across 581 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

Monash University is the lead sponsor of 83 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PROMPT - Inclusion Criteria:

  • Adult patient (≥18 years of age at time of admission)
  • Scheduled to undergo a surgical procedure involving a skin incision, with an expected duration of at least 2 hours, and a planned overnight hospital stay of at least 1 night (including, but not limited to, cardiac surgery, orthopedic surgery, obstetric, or gynecological surgery).

PROMPT - Exclusion Criteria:

  • 5 (moribund, not expected to survive with or without an operation)
  • Inability to provide
  • Previous participation in PROMPT within the prior 30 days.

DSA 02 - PROMPT - Exclusion Criteria:

  • ASA physical status 1 or 2
  • Undergoing cardiac surgery
  • Undergoing thoracic surgery if one-lung ventilation is required
  • Currently suspected or proven infection
  • Advanced lung disease requiring home oxygen therapy
  • Previous bleomycin therapy
  • Known or suspected pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
7,800 participants (estimated)

Study arms

  • Active comparator
    Liberal inspired oxygen

    FiO2 0.8; i.e. 80%

    Drug: Liberal inspired oxygen

  • Active comparator
    Conservative inspired oxygen

    FiO2 ≤0.3 \[30%\]

    Drug: Conservative inspired oxygen

  • Active comparator
    Intermediate inspired oxygen

    FiO2 0.5 \[50%\]

    Drug: Intermediate inspired oxygen

Interventions

  • DrugLiberal inspired oxygen

    The concentration of Oxygen will differ according to the randomisation

  • DrugConservative inspired oxygen

    Conservative inspired oxygen

  • DrugIntermediate inspired oxygen

    Intermediate inspired oxygen

06

What researchers measure

Primary outcomes

  1. Surgical Site Infection

    A post operative infection that develops at the site of an operation, caused by bacteria entering the body through the surgical incision

    Time frame: 30 days

Secondary outcomes

  1. Health Care Associated Infections

    pneumonia, blood stream infection and urinary tract infection

    Time frame: 30 days

  2. Quality of recovery

    Quality of the individual's recovery post surgery - PROM. The scores of all 15 questions, with each item rated on a scale that results in a total score ranging from 0 (very poor recovery) to 150 (excellent recovery)

    Time frame: 3 and 30 days after surgery

  3. major postoperative complications

    Description: A composite (and individually): Cardiovascular events (myocardial infarction, arterial or venous thrombosis, stroke, acute pulmonary edema, cardiogenic shock, new cardiac arrhythmia requiring treatment) Sepsis or septic shock (defined according to the Sepsis-3 definition)25 Respiratory complications - (i) pneumonia using US Centers for Disease Control criteria, (ii) Acute Respiratory Distress Syndrome using Berlin consensus definition, or (iii) the need for tracheal re-intubation and mechanical ventilation after extubation, and within 30 days after surgery OR mechanical ventilation for more than 24 h after surgery26 Unplanned intensive care unit (ICU) admission or readmission, defined as not anticipated preoperatively Acute kidney injury (based on the serum creatinine item of the Kidney Disease Improving Global Outcome criteria) Need for surgical re-intervention within 30 days after surgery Death within 30 days after surgery. Time Frame: 30 days

    Time frame: 30 days

  4. Mortality

    All cause

    Time frame: 30 days

  5. EQ-5D-5L

    Quality of life (EQ-5D-5L) at 30 days after index surgery. The resulting EQ-5D index score is a numerical value, with 1 representing full health, and scores less than 1 representing poorer health states, including negative values that indicate health states worse than death.

    Time frame: 30 days

  6. DAH 30

    Days alive and at home at 30 days (DAH30) after index surgery (reflecting the patient's primary aim of a healthy recovery, reduced hospital costs and the impact/severity of serious complications, and avoiding re-admission (often due to SSI).

    Time frame: 30 days

Other outcomes

  1. Cost Analysis

    Direct health care costs at 30 days after index surgery Number of quality-adjusted life years (QALYs) at 30 days after index surgery Cost effectiveness measured as a cost per QALY.

    Time frame: 30 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Dependent on Ethics Committee (IRB) approval, a clinically important hypothesis and valid protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07186634
Lead sponsor
Monash University
Collaborators
The Alfred, Wellington Hospital
Responsible party
Sponsor
First posted
Sep 22, 2025
Start date
Apr 6, 2026
Primary completion
Dec 2035 (estimated)
Completion
Dec 2035 (estimated)
Last update
Apr 17, 2026

Study contacts

Paul S Myles, DSc
Contact
p.myles@alfred.org.au
+6190762000 ext. 63176
Trisha Peel, PhD
Contact
trisha.peel@monash.edu
+61 3 9076 5436
Paul s Myles, DSc
principal investigator · Monash University
Trisha Peel, PhD
principal investigator · Monash University
Daniel Frei, PhD
principal investigator · Wellington Reginal Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion